Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Net Cash Flow (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Net Cash Flow data on record, last reported at $81.2 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 156.79% year-over-year to $81.2 million; the TTM value through Dec 2025 reached $155.5 million, up 208.48%, while the annual FY2025 figure was $155.5 million, 208.48% up from the prior year.
  • Net Cash Flow reached $81.2 million in Q4 2025 per COLL's latest filing, up from $32.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $95.8 million in Q1 2023 and bottomed at -$108.9 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $3.8 million, with a median of $12.1 million recorded in 2022.
  • The widest YoY moves for Net Cash Flow: up 680.51% in 2022, down 1019.16% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$6.8 million in 2021, then surged by 680.51% to $39.6 million in 2022, then tumbled by 149.5% to -$19.6 million in 2023, then surged by 261.37% to $31.6 million in 2024, then soared by 156.79% to $81.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $81.2 million in Q4 2025, $32.8 million in Q3 2025, and $21.2 million in Q2 2025.